Schizophrenia: a subcortical neurotransmitter imbalance syndrome?

Recent animal experiments suggest that glutamate plays a fundamental role in the control of psychomotor activity. This is illustrated by the finding that even in the virtually complete absence of dopamine, a marked behavioral activation is produced in mice following suppression of glutamatergic neurotransmission. This article discusses the possibility that a deficient activity within the cortico-striatal glutamatergic pathway is an important pathophysiological component in some cases of schizophrenia and that glutamatergic agonists may prove beneficial in this disorder. In a broader perspective, schizophrenia may be looked upon as a syndrome induced by a neurotransmitter imbalance in a feedback-regulated system, where dopamine and glutamate play a crucial role in controlling arousal and the processing of signals from the outer world to the cerebral cortex via the thalamus.

[1]  J. Robson,et al.  Recent Advances in Pharmacology , 1951, Canadian Medical Association journal.

[2]  A. Mcghie,et al.  Disorders of attention and perception in early schizophrenia. , 1961, The British journal of medical psychology.

[3]  P. Venables,et al.  INPUT DYSFUNCTION IN SCHIZOPHRENIA. , 1964, Progress in experimental personality research.

[4]  B. Maher,et al.  Progress in experimental personality research , 1964 .

[5]  Lehmann He.  Pharmacotherapy of schizophrenia. , 1966 .

[6]  L. Lunsky.  Psychopathology of Schizophrenia. , 1967 .

[7]  J. Stevens.  An anatomy of schizophrenia? , 1973, Archives of general psychiatry.

[8]  A. Freedman,et al.  Psychopathology and psychopharmacology , 1973 .

[9]  J. Villablanca,et al.  Effects of caudate nuclei or frontal cortical ablations in cats. I. Neurology and gross behavior , 1976, Experimental Neurology.

[10]  S. Iversen.  Brain Dopamine Systems and Behavior , 1977 .

[11]  A Carlsson,et al.  Antipsychotic drugs, neurotransmitters, and schizophrenia. , 1978, The American journal of psychiatry.

[12]  Borison Rl.  Pharmacology of antipsychotic drugs. , 1985 .

[13]  P. Goldman-Rakic,et al.  Longitudinal topography and interdigitation of corticostriatal projections in the rhesus monkey , 1985, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[14]  George Paxinos,et al.  Forebrain and midbrain , 1985 .

[15]  P. Goldman-Rakic,et al.  Topography of Corticostriatal Projections in Nonhuman Primates and Implications for Functional Parcellation of the Neostriatum , 1986 .

[16]  G. E. Alexander,et al.  Parallel organization of functionally segregated circuits linking basal ganglia and cortex. , 1986, Annual review of neuroscience.

[17]  L. Iversen,et al.  The anticonvulsant MK-801 is a potent N-methyl-D-aspartate antagonist. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[18]  P. Bradley,et al.  The Psychopharmacology and treatment of schizophrenia , 1986 .

[19]  L. DeLisi,et al.  Neurochemistry and Neuropharmacology of Schizophrenia , 1987 .

[20]  P. Venables.  Cognitive and Attentional Disorders in the Development of Schizophrenia , 1987 .

[21]  T. Hicks,et al.  Excitatory amino acid transmission , 1987 .

[22]  M. Delong,et al.  A reappraisal of the functions of the nucleus basalis of Meynert , 1988, Trends in Neurosciences.

[23]  H. Narabayashi.  Lessons from stereotaxic surgery using microelectrode techniques in understanding parkinsonism. , 1988, The Mount Sinai journal of medicine, New York.

[24]  G. Sedvall,et al.  Central D2-dopamine receptor occupancy in schizophrenic patients treated with antipsychotic drugs. , 1988, Archives of general psychiatry.

[25]  S. Iversen,et al.  Handbook of Psychopharmacology , 1988, Springer US.

[26]  W. Schmidt,et al.  Behavioural effects of N-methyl-D-aspartate in the anterodorsal striatum of the rat. , 1988, Life sciences.

[27]  A Carlsson,et al.  The current status of the dopamine hypothesis of schizophrenia. , 1988, Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology.

[28]  R. Raffa,et al.  In vivo demonstration of the enhancement of MK-801 by L-glutamate. , 1989, Life sciences.

[29]  Leonard S. Zegans,et al.  Neurology and psychiatry : a meeting of minds , 1989 .

[30]  J. Stevens.  The Search for an Anatomic Basis of Schizophrenia: Review and Update , 1989 .

[31]  A. Carlsson,et al.  Marked locomotor stimulation in monoamine-depleted mice following treatment with atropine in combination with clonidine , 1989, Journal of neural transmission. Parkinson's disease and dementia section.

[32]  M. Carlsson,et al.  Interfering with glutamatergic neurotransmission by means of MK-801 administration discloses the locomotor stimulatory potential of other transmitter systems in rats and mice , 1990 .

[33]  A. Carlsson,et al.  Interactions between glutamatergic and monoaminergic systems within the basal ganglia-implications for schizophrenia and Parkinson's disease , 1990, Trends in Neurosciences.

[34]  Bradley V. Clineschmidt,et al.  Central sympathomimetic activity of (+)‐5‐methyl‐10,11‐dihydro‐5H‐dibenzo [a, d]cyclohepten‐5,10‐imine (MK‐801), a substance with potent anticonvulsant, central sympathomimetic, and apparent anxiolytic properties , 2022 .